Thermo Fisher launches new test; detecting current and future mutations

Thermo Fisher Scientific has launched a new CE-IVD-marked COVID-19 test. The TaqPath COVID-19 Fast PCR Combo Kit 2.0. expands Thermo Fisher's range of tests that detect active SARS-CoV-2 infections.

The kit uses an assay design which compensates for current and emerging variants by using eight total targets across three genomic regions of the virus. This approach helps to ensure the test provides accurate results even as the virus that causes COVID-19 continues to mutate.

Manoj Gandhi, M.D., Ph.D., senior medical director, genetic sciences for Thermo Fisher, said: "COVID-19 variants can be more transmissible and potentially impact efficacy of diagnostics, vaccines and therapies, threatening to reverse progress made in the past year. We are working to empower our customers to prepare for the next stage of the pandemic by future-proofing our test design against likely mutations and to provide continued confidence in their results."

The TaqPath COVID-19 Fast PCR Combo Kit 2.0 test assesses raw saliva directly with a turnaround time of two hours to enable widespread, high-frequency testing.